trending Market Intelligence /marketintelligence/en/news-insights/trending/59gbv72k5ak5_n5qq0fnfg2 content esgSubNav
In This List

Immunomedics prices $276M common stock offering


Baird Research is Now Exclusively Available in S&P Global’s Aftermarket Research Collection


Japan M&A By the Numbers: Q4 2023


Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity

Immunomedics prices $276M common stock offering

Immunomedics Inc. priced its public offering of common stock to raise about $276 million in gross proceeds.

The Morris Plains, N.J.-based biopharmaceutical company is issuing 11.5 million common shares at $24 apiece.

Immunomedics granted the underwriters an option to buy up to an additional 1,725,000 shares.

The company plans to use net proceeds from the offering for accelerating the clinical development program of sacituzumab govitecan for solid cancers, manufacturing process improvements, and for working capital and general corporate purposes.

The offering is expected to close June 15, subject to customary closing conditions.

Morgan Stanley, Cowen and Jefferies are acting as book-running managers, while Wells Fargo Securities is serving as lead manager for the offering.